Global Partners LP GLP
42.95 USD +1.49 (+3.59%)
At closeNov 10, 2026, 4:00 PM EST
42.95 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
41.50 Day range 43.10
39.58 52-week range 54.29
- YTD
- +2.63%
- 1 year
- +5.58%
News
seekingalpha.com Hims & Hers Health: Don't Nitpick Quarterly Results Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. HIMS strategically reduced marketing spend to prepare for the Eli Lilly…
fool.com Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? Eli Lilly has been generating incredible growth in recent quarters due to its top GLP-1 drugs. Novo Nordisk has struggled due to sluggish numbers, but a higher-dose version of Wegovy could change…
globenewswire.com Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue Restoration Highlights Conexeu has launched a human collagen initiative at its Vancouver research and development facility, for its aesthetics program, focused on potential tissue-restoration applications…
globenewswire.com Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026 SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that…
cnbc.com FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of…
247wallst.com Eli Lilly May Have Just Found a New $23 Billion Market for Its GLP-1 Pill Eli Lilly (NYSE:LLY | LLY Price Prediction) just gave its newest drug a second act.
247wallst.com Global Partners Yields 7.15%. Is Its Dividend Safe? Twenty straight quarterly raises sound reassuring, but a wholesale margin windfall and softening retail demand are pulling in opposite directions at Global Partners. Which of those forces will decide…
zacks.com Here's Why Global Partners (GLP) Is a Great 'Buy the Bottom' Stock Now Global Partners (GLP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could…
globenewswire.com Zealand Pharma announces Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits Company announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in…
prnewswire.com Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications – HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported…
marketbeat.com What Global Partners (GLP) Said on Its Q3 Earnings Call Global Partners NYSE: GLP reported higher third-quarter earnings as stronger wholesale margins more than offset lower retail fuel volumes, which executives attributed to higher pump prices.
seekingalpha.com Global Partners LP Common Units (GLP) Q3 2026 Earnings Call Transcript Global Partners LP Common Units (GLP) Q3 2026 Earnings Call Transcript
marketwatch.com Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying. As part of the agreement, Hims said it won't compound GLP-1 medications like Zepbound in the future.
zacks.com Should Value Investors Buy Global Partners (GLP) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
benzinga.com Global Partners Q3 2026 Earnings Call Transcript Global Partners (NYSE:GLP) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This content is powered by…
benzinga.com Global Partners Q3 EPS $1.26 Misses $1.61 Estimate, Sales $6.684B Miss $7.412B Estimate Global Partners (NYSE:GLP) reported quarterly earnings of $1.26 per share which missed the analyst consensus estimate of $1.61 by 21.74 percent. This is a 90.91 percent increase over earnings of…
businesswire.com Global Partners LP Reports Third-Quarter 2026 Financial Results NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2026. CEO Commentary…
defenseworld.net Reviewing Global Partners (NYSE:GLP) & Murphy Oil (NYSE:MUR) Murphy Oil (NYSE: MUR - Get Free Report) and Global Partners (NYSE: GLP - Get Free Report) are both energy companies, but which is the superior stock? We will compare the two companies based on the…
zacks.com Is Global Partners (GLP) a Solid Growth Stock? 3 Reasons to Think "Yes" Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
barrons.com Don't Lose Sleep Over GLP-1s: Why ResMed Is a Bargain ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
reuters.com GLP-1 drugs help control prediabetes better than current standard medicine Today we feature a trio of interesting studies that will be presented in detail at the American Heart Association scientific sessions in Chicago this weekend.